Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $1,000.00 by Analysts at JPMorgan Chase & Co.

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective lowered by JPMorgan Chase & Co. from $1,100.00 to $1,000.00 in a research report sent to investors on Monday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical company’s stock.

Several other research analysts have also recently issued reports on REGN. Sanford C. Bernstein dropped their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Piper Sandler dropped their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. Robert W. Baird lowered their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research note on Wednesday, February 5th. Citigroup dropped their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Finally, UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $966.88.

Regeneron Pharmaceuticals Stock Down 0.5 %

Shares of REGN opened at $634.23 on Monday. The firm has a market capitalization of $69.34 billion, a P/E ratio of 16.57, a P/E/G ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals has a 12-month low of $618.51 and a 12-month high of $1,211.20. The firm has a fifty day moving average price of $682.93 and a 200-day moving average price of $791.84. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the company earned $11.86 EPS. Equities research analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.56%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 2.30%.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. D.A. Davidson & CO. grew its holdings in shares of Regeneron Pharmaceuticals by 5.1% during the third quarter. D.A. Davidson & CO. now owns 821 shares of the biopharmaceutical company’s stock valued at $863,000 after buying an additional 40 shares during the last quarter. Quantbot Technologies LP purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at about $151,000. Public Sector Pension Investment Board increased its holdings in shares of Regeneron Pharmaceuticals by 13.0% in the third quarter. Public Sector Pension Investment Board now owns 4,341 shares of the biopharmaceutical company’s stock valued at $4,563,000 after purchasing an additional 500 shares during the period. Hantz Financial Services Inc. raised its stake in shares of Regeneron Pharmaceuticals by 87.2% in the third quarter. Hantz Financial Services Inc. now owns 73 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 34 shares during the last quarter. Finally, Captrust Financial Advisors lifted its holdings in shares of Regeneron Pharmaceuticals by 3.4% during the third quarter. Captrust Financial Advisors now owns 9,130 shares of the biopharmaceutical company’s stock worth $9,597,000 after purchasing an additional 296 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.